Victoria M. Villaflor, MD
Molecular abnormalities in non–small cell lung cancer (NSCLC) need to be recognized and tested for, explained Victoria M. Villaflor, MD, which means evaluating and referring more patients to clinical trials.
on Advanced Non–Small Cell Lung Cancer, Villaflor, an associate professor of medicine at Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, discussed driver mutations in NSCLC and remaining challenges in treating patients with targetable disease.
OncLive: Can you please provide an overview of your lecture?
Essentially, I spoke about many different molecular driver mutations and translocations that can occur in lung cancer. We covered ALK, ROS1, BRAF V600E,
and we talked a little bit about HER2/neu, RET,
... to read the full story